Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Tislelizumab(T) as Neoadjuvant Treatment for Cisplatin-ineligible High Risk Upper Tract Urothelial Carcinoma (UTUC)

NCT04672330 is registered in ClinicalTrials.gov with RenJi Hospital as lead sponsor.

NCT NCT04672330
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04672330 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Tislelizumab(T) as Neoadjuvant Treatment for Cisplatin-ineligible High Risk Upper Tract Urothelial Carcinoma (UTUC)
Lead sponsor
RenJi Hospital
Phase
Phase 2
Overall status
Completed
Start date
December 1, 2020
Completion date
November 25, 2023
Enrollment
16 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

neoadjuvant immunotherapy of cisplatin-ineligible high risk upper urinary tract urothelial carcinoma